atomoxetine / Generic mfg. - LARVOL DELTA

Chronic Administration of Atomoxetine and Methylphenidate Induces Differential Alterations in the Hippocampus and Striatum of Young Rats. (PubMed, Neurotox Res) - No abstract available

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Connecting the dots and finding the way forward: Pharmacological, neuromodulatory, and psychotherapeutic interventions for the complex treatment of adult ADHD. (PubMed, Pharmacol Ther) - "Treatment emphasizes multimodal approaches, with stimulants as first-line pharmacotherapy due to their superior efficacy over non-stimulants like atomoxetine and viloxazine. Novel agents in development, such as centanafadine triple reuptake inhibitor and solriamfetol target core symptoms and comorbidities, showing promising phase III results...Psychotherapeutic options, particularly cognitive-behavioral therapy (CBT)-based interventions, improve symptom management and emotional regulation, often as adjuncts to medication. The review highlights the need for personalized strategies addressing adherence, comorbidity, and long-term outcomes, emphasizing integrated care to mitigate ADHD's lifelong impact."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Cognitive Disorders • Mood Disorders • Psychiatry

Populational pharmacokinetics of methylphenidate hydrochloride extended-release tablets in Chinese school-age children with attention-deficit/hyperactivity disorder (ChiCTR) - P=N/A | N=60 | Completed | Sponsor: Children's Hospital of Chongqing Medical University; Children's Hospital of Chongqing Medical University

New trial • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Drug-related suicidal events in children and teenagers: Age-stratified insights from FAERS. (PubMed, Leg Med (Tokyo)) - "Across FAERS youth suicide reports, drug-associated fatality risk varies markedly by drug, surges in mid- to late adolescence, diverges by sex and shifts at both age extremes. These heterogeneities underscore the need for age-appropriate pharmacovigilance and trial strategies rather than direct extrapolation from adult data, particularly regarding the safety of drugs associated with suicide."

Journal • Pediatrics

Atomoxetine for encopresis in children with autism spectrum disorder: Report of 4 cases. (PubMed, Psychiatr Danub) - No abstract available

Journal • Autism Spectrum Disorder • Genetic Disorders

Efficacy and safety of atomoxetine in the treatment of ADHD in children and adolescents: a systematic review. (PubMed, Front Child Adolesc Psychiatry) - "Atomoxetine demonstrated comparable efficacy to methylphenidate in reducing ADHD symptoms. Continued research, especially long-term studies, is necessary to confirm its efficacy across different patient subgroups. Identifier CRD420251152121."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fatigue • Psychiatry

Biomarkers for predominantly inattentive ADHD: potential involvement of Wnt/β-catenin/integrin signaling in a spontaneously hypertensive rat. (PubMed, Genes Genomics) - "Dysregulation of Wnt/β-catenin/integrin signaling may contribute to the ADHD pathophysiology. Concordant upregulation of Ctnnβ1 and Itgβ1 in brain and peripheral blood may support their potential as peripheral biomarkers of ADHD. Responsiveness of these genetic markers to atomoxetine treatment indicates potential value for treatment monitoring and supports targeting this pathway in future therapeutic strategies."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Developmental Disorders • Psychiatry • ITGB1

Differential working memory changes following methylphenidate in medication-naive and medication-experienced adults with ADHD. (PubMed, PCN Rep) - "A sensitivity analysis excluding atomoxetine-experienced participants showed a preserved effect size but trend-level significance (q = 0.061). Rather than reflecting a purely pharmacological effect, these patterns may involve a combination of baseline cognitive differences, learned cognitive strategies, and pre-existing individual characteristics. These preliminary findings highlight the importance of considering treatment history in clinical practice and research."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Update on pharmacogenetics in pediatrics. (PubMed, An Pediatr (Engl Ed)) - "Drug-gene pairs with greater use in pediatrics are presented in more detail, such as proton pump inhibitors and CYP2C19, Abacavir, allopurinol, carbamazepine, oxcarbazepine, and phenytoin with HLA-A and HLA-B genes, voriconazole and CYP2C19, tacrolimus and CYP3A5, aminoglycosides and MT-RNR1, thiopurines and TMPT/NUDT15, or atomoxetine and CYP2D6. Despite current limitations, the use of pharmacogenetics in pediatrics can and should be implemented in those cases where regulatory agencies and/or scientific societies recommend it."

Biomarker • Journal • Pediatrics • CYP2C19 • CYP3A5 • HLA-B • NUDT15

Drug-induced phospholipidosis of the kidney suspected to be caused by atomoxetine. (PubMed, J Pathol Transl Med) - "When zebra bodies are observed, clinicians should consider DIP caused by cationic amphiphilic drugs alongside Fabry disease. Atomoxetine meets the structural criteria for inducing DIP, and awareness of this potential complication is essential."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Fabry Disease • Fibrosis • Genetic Disorders • Immunology • Inflammation • Lysosomal Storage Diseases • Metabolic Disorders • Psychiatry • Rare Diseases • Renal Disease

STAM1-deficient mice exhibit an attention-deficit/hyperactivity disorder-like phenotype. (PubMed, Biochem Biophys Res Commun) - "The ADHD therapeutic agent atomoxetine ameliorated ADHD-like impulsivity observed in STAM1-deficient mice; STAM1-deficient mice treated with the dopamine D4 receptor antagonist clozapine, but not the dopamine D2 receptor antagonist haloperidol, showed reduced ADHD-like impulsivity. These results indicate that STAM1-deficient mice show ADHD-like symptoms, suggesting the possibility of a new ADHD animal model. Moreover, clozapine may be a new therapeutic agent for ADHD."

Journal • Preclinical • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Psychiatry • DRD2

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease (clinicaltrials.gov) - P1 | N=23 | Completed | Sponsor: Hubert Fernandez | Recruiting ➔ Completed | N=42 ➔ 23 | Trial completion date: Dec 2028 ➔ Dec 2025 | Trial primary completion date: Dec 2027 ➔ Dec 2025

Enrollment change • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

AnTi-FREEZE: Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach (clinicaltrials.gov) - P3 | N=60 | Not yet recruiting | Sponsor: Radboud University Medical Center

New P3 trial • CNS Disorders • Movement Disorders • Parkinson's Disease

Prescribed Drugs and Interpersonal Violence: A Case-Non-Case Study in the Spanish Pharmacovigilance Database. (PubMed, Pharmaceuticals (Basel)) - "Mostly drugs reported were montelukast, levetiracetam, bupropion, donepezil, perampanel, quetiapine, fluoxetine, and lorazepam. A statistically significant association/disproportion in the notification has been found in the reporting of interpersonal violence and different drugs according to the literature, notably atomoxetine, perampanel, memantine, donepezil, montelukast and methylphenidate. The results highlight that interpersonal violence, while rare, could occur as a clinically relevant adverse reaction to a small subset of medications. They underscore the importance of careful prescribing, especially in vulnerable populations and in individuals with a history of psychiatric disorders."

Adverse events • Journal • CNS Disorders • Mental Retardation • Psychiatry

Priapism associated with atomoxetine use (PubMed, Tijdschr Psychiatr) - "The literature includes several cases describing atomoxetine-induced priapism in children and adolescents. This case, in which an adult male experienced priapism as a side effect of atomoxetine, highlights the importance of being vigilant for this potential complication when prescribing the drug, including in adult patients."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pain • Psychiatry

Effectiveness of Pharmacological Treatments for Adult ADHD on Psychiatric Comorbidity: A Systematic Review. (PubMed, J Clin Med) - "This systematic review evaluated the effectiveness of commonly prescribed medications for adult ADHD (methylphenidate, atomoxetine, bupropion, and lisdexamfetamine) on comorbid mood, anxiety, personality, and substance use disorders. Tricyclic antidepressants were also included in the search strategy; however, no eligible adult studies assessing imipramine or desipramine in patients with ADHD and psychiatric comorbidity were identified...While targeted improvements may occur in specific domains, the evidence base is insufficient to define optimal long-term strategies for adults with ADHD and complex comorbidity. Rigorous, longitudinal studies are needed to clarify medication effects on distinct comorbid profiles and to inform integrated treatment planning."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Mood Disorders • Personality Disorder • Psychiatry

Drug Development. (PubMed, Alzheimers Dement) - "We present a practical approach to prioritising repurposed drugs to evaluate in the context of clinical AD. We would like to thank our patient and public contributors and the wider investigator team."

Journal • Alzheimer's Disease • CNS Disorders • Psychiatry

Development and validation of a rapid LC-MS/MS method for methylphenidate, atomoxetine, and their metabolites with application to pediatric pharmacokinetics. (PubMed, J Pharm Biomed Anal) - "No significant associations were observed with age, sex, or body mass index. This rapid and reliable LC-MS/MS platform supports clinically actionable therapeutic drug monitoring and provides a practical framework for personalized ADHD treatment."

Journal • PK/PD data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Pediatrics • Psychiatry

Atomoxetine as a Viable ADHD Treatment in Breastfeeding Mothers: Evidence From Human Milk Pharmacokinetic Analysis. (PubMed, J Clin Psychopharmacol) - "The transfer of atomoxetine into human milk is minimal, with a 0.19% RID, well below the 5% safety threshold for psychoactive medications. The minimal transfer suggests that maternal atomoxetine use poses a very low risk to breastfed infants, making it a suitable choice for medication management of ADHD in lactating women."

Journal • PK/PD data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Sexual Functioning in Individuals With Attention-Deficit Hyperactivity Disorder: A Narrative Review. (PubMed, Cureus) - "Some authors emphasize the importance of neurobiological mechanisms such as "dopaminergic craving" or novelty-seeking, while others indicate that hypersexual behaviors may be treated as a form of self-regulation. Concerning pharmacotherapy, psychostimulant drugs (e.g., methylphenidate and lisdexamfetamine) and nonstimulants (e.g., atomoxetine and clonidine) demonstrate both beneficial and adverse impacts on sexual functioning, although empirical data are limited. ADHD shows a significant correlation with the occurrence of a wide spectrum of sexual disorders, which requires consideration in diagnostics and treatment planning. The high prevalence of hypersexuality, CSBD, and RSD highlights the need for an interdisciplinary approach combining pharmacological interventions with psychotherapy focused on emotional regulation, improvement of interpersonal relationships, and reduction of risky behaviors. Further research..."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Behavior Disorders • CNS Disorders • Mental Retardation • Pediatrics • Psychiatry • Sexual Disorders

Efficacy of computer-assisted cognitive flexibility training and the moderating role of neuroticism in children with ADHD: A randomized controlled trial. (PubMed, Behav Res Ther) - "Targeted CFT demonstrated near-transfer cognitive gains and was associated with parent-reported improvements in some functional domains. Given its distinct profile from pharmacotherapy, CFT may be a promising adjunct, rather than a standalone treatment, for children with ADHD, particularly those with lower neuroticism."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Clinical Features and Comparative Treatment Outcomes of Atomoxetine and Methylphenidate in Omani Adults with ADHD. (PubMed, Oman Med J) - "Male sex and the absence of a family history of ADHD were associated with greater response to treatment. These factors may serve as clinical indicators for tailoring pharmacological treatment decisions for individual adult ADHD patients in Oman."

Journal • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry

Effects of medications on sleep quality, insomnia, and circadian rhythm in adults with ADHD: A pragmatic longitudinal study. (PubMed, Sleep Med) - "Pharmacological treatment, particularly with stimulants and non-stimulants, may stabilize sleep in adults with ADHD. Coexistence of psychiatric disorders and antidepressant use negatively affect sleep. ASD traits did not show independent effects on sleep when controlling for other factors. Comprehensive, individualized care is essential in this population."

Journal • Observational data • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Insomnia • Mental Retardation • Psychiatry • Sleep Disorder • Sleep Wake Cycle Disorder

Classification, diagnosis and therapy of attention deficit hyperactivity disorder (PubMed, Zh Nevrol Psikhiatr Im S S Korsakova) - "Age-related features of ADHD, gender differences are noted, the results of short-term and long-term courses of atomoxetine use are summarized, the results of randomized studies on the positive effect of the drug on the socialization of patients, academic performance and the possibility of correcting comorbid anxiety syndromes, autistic disorders and syncopal states are presented. In domestic practice of ADHD therapy, Atomoxetine it is a first-line drug."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • Autism Spectrum Disorder • CNS Disorders • Genetic Disorders • Mood Disorders • Psychiatry • Sleep Disorder

Is the ADHD bomb about to explode? The impact of the medicalization of attention-deficit/hyperactivity disorder on its pharmacotherapy and institutional context in Hungary (PubMed, Orv Hetil) - "It provides a detailed discussion of the benefits and risks of methylphenidate, the issue of misuse, and the role of atomoxetine as an alternative. Orv Hetil. 2025; 166(49): 1935-1942."

Journal • Review • ADHD (Impulsive Aggression) • Attention Deficit Hyperactivity Disorder • CNS Disorders • Psychiatry